- AMGN -0.03%
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
Yahoo Finance · 5 hours ago
Search results
- 299.38Add to watchlist-0.10 (-0.03%)As of Tue. May 7, 2024 2:00 PM EDT · Nasdaq Real Time Price (USD) · Market open
- Open301.75High302.91Low298.74
- Mkt Cap160.6BP/E (TTM)42.71Div & Yield9.00 & 3.00%
- Prev. Close299.4852 Wk. Low211.7152 Wk. High329.72
What analysts are sayingTop storiesRelated stocks
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and ...
Live. Win. Thrive. We dare to ask questions that lead to lifesaving treatments. Join us in pushing the boundaries of biotechnology in a career at Amgen.
Amgen is a pioneer in the science of using living cells to make biologic medicines. We helped invent the processes and tools that built the global biotech industry—turning it into a leading source of therapies for patients.
Corporate Headquarters. One Amgen Center Drive. Thousand Oaks, CA. 91320-1799. +1 805-447-1000.
Jan 31, 2023 · THOUSAND OAKS, Calif., Jan. 31, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced AMJEVITA™ (adalimumab-atto), a biosimilar to Humira ®* (adalimumab), is now available in the United States. AMJEVITA was the first biosimilar to Humira approved by the U.S. Food and Drug Administration (FDA), in 2016. 2,3.
Amgen | 1,190,102 followers on LinkedIn. #WeareBiotech | Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing ...
Amgen Releases 8th Edition of Biosimilar Trends Report. Report Finds That Competition Created by Biosimilars Delivered $9.8 Billion in Savings Over the Past Five Years to the U.S. Healthcare System, Generating Savings for Patients, Payers and Employers.
